BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2022 6:32:13 AM | Browse: 365 | Download: 745
 |
Received |
|
2022-05-09 01:28 |
|
Peer-Review Started |
|
2022-05-09 01:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-16 10:43 |
|
Revised |
|
2022-07-06 22:52 |
|
Second Decision |
|
2022-08-29 03:59 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-31 04:31 |
|
Articles in Press |
|
2022-08-31 04:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-09-14 06:40 |
|
Publish the Manuscript Online |
|
2022-09-22 06:32 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Carlos Aguado, Unai Jiménez Maestre and Xabier Mielgo-Rubio |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Carlos Aguado, MD, Consultant Physician-Scientist, Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Calle del Prof Martín Lagos, Madrid 28040, Spain. carlos.aguado84@gmail.com |
| Key Words |
Neoadjuvant; Immunotherapy; NSCLC; Perioperative; Checkmate-816; nivolumab; Chemo-immunotherapy |
| Core Tip |
Recent data from a phase 3 trial show that the addition of immunotherapy to neoadjuvant chemotherapy in patients with non-small-cell lung cancer (NSCLC) improves pathologic complete response and event-free survival. This is the first positive phase 3 trial in this setting, although several other phase 3 studies are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC. We describe the results of the CheckMate-816 phase 3 trial, which found that neoadjuvant chemoimmunotherapy was superior to chemotherapy alone. We also briefly review the main phase 3 studies currently underway to evaluate the role of immunotherapy in the perioperative setting of NSCLC. |
| Publish Date |
2022-09-22 06:32 |
| Citation |
Aguado C, Maestre UJ, Mielgo-Rubio X. Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast. World J Clin Oncol 2022; 13(9): 758-761 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i9/758.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i9.758 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
